Last Updated: August 2, 2026

CEFTRIAXONE Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

When do Ceftriaxone patents expire, and what generic alternatives are available?

Ceftriaxone is a drug marketed by Acs Dobfar, Agila Speclts, Apotex, Aurobindo Pharma Ltd, Bedford, Facta Farma, Fresenius Kabi Usa, Hospira Inc, Lupin, Qilu Antibiotics, Samson Medcl, Sandoz, Sandoz Inc, Teva, Astral, Cephazone Pharma, Deva Holding As, Epic Pharma Llc, Hikma Farmaceutica, Teva Pharms Usa, Wockhardt Bio Ag, B Braun, Baxter Hlthcare, Anda Repository, and Hikma. and is included in thirty-seven NDAs.

The generic ingredient in CEFTRIAXONE is ceftriaxone sodium. There are twenty-six drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the ceftriaxone sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ceftriaxone

A generic version of CEFTRIAXONE was approved as ceftriaxone sodium by ANDA REPOSITORY on January 20^th, 2017.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for CEFTRIAXONE?
What are the global sales for CEFTRIAXONE?
What is Average Wholesale Price for CEFTRIAXONE?

Summary for CEFTRIAXONE

US Patents:	0
Applicants:	25
NDAs:	37

US Patents and Regulatory Information for CEFTRIAXONE

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	CEFTRIAXONE	ceftriaxone sodium	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS	065169-002	May 9, 2005	AP	RX	No	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Deva Holding As	CEFTRIAXONE	ceftriaxone sodium	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS	210197-001	Jan 12, 2024		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Bedford	CEFTRIAXONE	ceftriaxone sodium	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS	065465-004	Aug 18, 2008		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Anda Repository	CEFTRIAXONE SODIUM	ceftriaxone sodium	INJECTABLE;INJECTION	091117-001	Jan 20, 2017	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.